Sandoz, the Swiss generic and biosimilar drugmaker, saw its shares tumble in trading on Wednesday as fresh competitive pressures in the biosimilar space rattled investor confidence. The stock fell by as much as 4.7% in early afternoon trading on the SIX Swiss Exchange, before recovering slightly to trade 3.8% lower by mid-session.
The sell-off was triggered by reports that a rival manufacturer had received regulatory approval for a biosimilar version of one of Sandoz’s key products in the United States. Analysts at Jefferies noted that the new entrant could erode Sandoz’s market share and force further price reductions in an already tightening market. “The biosimilar landscape is becoming increasingly crowded, and Sandoz is feeling the pinch,” one analyst said.
The broader European healthcare sector also felt the impact, with the STOXX Europe 600 Health Care index slipping 0.6% on the day. For UK investors, the move is a reminder of the volatility inherent in pharmaceutical investments, particularly those exposed to biosimilars, which are often subject to aggressive pricing dynamics. Many UK pension funds and unit trusts hold positions in European healthcare stocks as part of diversified portfolios.
Context: Sandoz, a Novartis subsidiary, has been a major player in the biosimilar market, which has grown rapidly over the past decade as patents on expensive biologic drugs expire. However, increased competition from both established players and emerging manufacturers in Asia has squeezed margins. The company has also faced supply chain challenges and regulatory hurdles in recent quarters.
Looking ahead, market watchers will be watching for any further regulatory approvals or pricing announcements that could shift the competitive landscape. For now, Sandoz’s management has not issued a formal statement on the day’s price movement, but analysts expect the company to provide an update during its next earnings call.